EFA Technologies

About EFA Technologies

EFA Technologies, standing for Engineering for All, is a medical technology firm focused on democratizing diagnostics. The company was founded in 2016 by CEO Yoel Ezra, who, after a 24-year military career and experience in the medical device field, was driven to create a solution for accessible healthcare. Initially targeting the eradication of Malaria, the company's focus pivoted to broader applications after participating in the Pears Challenge and the eHealth Ventures Incubator. A significant milestone was achieved in April 2024, when EFA Technologies announced its entry into the Brazilian market following regulatory approval from Anvisa for its device, coupled with securing $6.5 million in a funding round led by existing and new investors.

The core of EFA's business is its flagship product, RevDx™, a portable, handheld hematology analyzer. This device is designed to perform a complete blood count (CBC), one of the most common medical tests, from a single drop of blood in under five minutes, directly at the point of care. It operates using a combination of automated microscopy and AI to deliver lab-grade results without needing specialized expertise, complex reagents, or calibration. The system is engineered for anyone to use, targeting healthcare providers in settings from remote locations to bustling clinics, and even home-care scenarios, thereby reducing the time and cost associated with traditional lab testing. The business model involves the sale of the RevDx™ device and the associated disposable test chips used for each blood sample. The company also plans to create a marketplace for developers to add health-apps for various conditions, positioning RevDx™ as a platform for future diagnostic needs.

The RevDx™ device weighs only 2.5kg and is battery-operated, making it fully portable. Its 'one-step' process involves taking a blood sample with a disposable chip, inserting the chip into the device, and receiving the results on-screen shortly after. This process minimizes risks for medical teams and improves the patient experience by providing immediate data for clinical decisions, which is crucial for managing infections and determining between viral or bacterial causes. The device's ability to digitally transfer images for remote analysis also supports telemedicine applications. EFA's advisory board includes prominent figures like 2004 Nobel Prize Laureate Prof. Aaron Ciechanover, underscoring the potential impact of its technology.